Treatment
Tislelizumab clinical trials
We’re tracking 219 recruiting studies that include Tislelizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06602011Recruiting
Triple therapy for advanced liver cancer with bile duct invasion
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Fuzhou, FujianAges 18–75 - NCT06647680RecruitingPhase 2
Chemo and immunotherapy before surgery for rectal cancer
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Qingdao, ShandongAges 18–75 - NCT06709885RecruitingPhase 2
HDAC inhibitor with chemoimmunotherapy before colon cancer surgery
This trial tests adding an HDAC inhibitor to standard chemotherapy and immunotherapy before surgery for a type of colon cancer called pMMR that has grown into nearby fat or deeper. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06722183RecruitingPhase 2
Futibatinib plus chemo-immunotherapy for advanced colorectal cancer
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
AmbergAges 18 years+ - NCT06725498RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06741982RecruitingPhase 1
Immune-targeted therapy and virus treatment before head and neck cancer surgery
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–70 - NCT06760858Recruiting
Study of treatment for advanced stomach cancer
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06848465RecruitingPhase 1
Radiation plus chemo-immunotherapy for colon cancer with liver spread
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06877299RecruitingPhase 2
Combination Therapy for Stage IIA-IIIB Lung Cancer
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
Chengdu, ChinaAges 18–75 - NCT07000617RecruitingPhase 2
A study of drugs plus radiation for early-stage NK/T-cell lymphoma
This trial tests a combination of the drugs dexamethasone, azacitidine, pegaspargase, and tislelizumab along with radiation therapy for people with stage I or II extranodal NK/T-cell lymphoma. The goal is to see if this treatment works well and is safe for patients who have not yet received treatment.
BeijingAges 18 years+ - NCT07019675RecruitingPhase 2
Study of a new drug for people with lung cancer
This trial tests a new medication, SKB518, for people with non-small cell or small cell lung cancer who have at least one measurable tumor and are in fairly good health. It aims to see if the drug can help shrink tumors or slow the cancer's growth.
Shenzhen, GuangdongAges 18–75 - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+ - NCT07244016Recruiting
TCR test to guide immunotherapy and chemo for extensive SCLC
This trial tests whether a blood test (TCR) can help predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works for people with extensive-stage small cell lung cancer (SCLC) that has not been treated before.
Zhengzhou, HenanAges 18 years+ - NCT07264647RecruitingPhase 2
Chemo-immunotherapy before surgery for stage III lung cancer
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Rome, Roma (RM)Ages 18–99 - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07339488RecruitingPhase 2
Low-dose radiation plus immunotherapy to shrink esophageal cancer before surgery
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
Shantou, GuangdongAges 18–75 - NCT07341360RecruitingEarly Phase 1
Cancer vaccine trial for pseudomyxoma peritonei
This trial tests a vaccine for people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that has come back or cannot be removed by surgery. The vaccine is designed to help the immune system fight the cancer. It is for people whose tumor has a specific genetic change (GNAS mutation) and who have no other standard treatment options.
Oslo, OsloAges 18 years+ - NCT07352280Recruiting
Immunotherapy before surgery for certain colorectal cancers
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Beijing, UndefinedAges 18 years+ - NCT07119996RecruitingPhase 1
Vitamin B3 to boost immunotherapy for bladder cancer
This trial tests whether taking vitamin B3 can help immunotherapy work better for people with bladder cancer. It’s for patients who have a certain type of bladder cancer and have had a recent infection that needed antibiotics.
Guangzhou, GuangdongAges 18 years+ - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+
Common questions
- Are there clinical trials studying Tislelizumab?
- Yes. Clin2 currently lists 219 recruiting studies that include Tislelizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tislelizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tislelizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tislelizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.